Evolent Health
EVH
155 hedge funds and large institutions have $987M invested in Evolent Health in 2020 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 37 increasing their positions, 53 reducing their positions, and 23 closing their positions.
132% more call options, than puts
Call options by funds: $5.88M | Put options by funds: $2.54M
89% more capital invested
Capital invested by funds: $522M → $987M (+$465M)
83% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 23
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
14% more funds holding
Funds holding: 136 → 155 (+19)
7.45% more ownership
Funds ownership: 85.95% → 93.39% (+7.4%)
30% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 53
Top Buyers
Top Sellers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$20.6M |
| 2 |
FG
Formula Growth
Montreal,
Quebec, Canada
|
-$17.3M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$8.47M |
| 4 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$8.29M |
| 5 |
BlackRock
New York
|
-$6.39M |
EVH Hedge Fund Activity: Q3 2020 in Review
155 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q3 2020, worth a combined $987M — up 89% from $522M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new EVH positions and 23 closed out — a net gain of 19 holders — while 37 added to existing stakes and 53 trimmed.
The largest buyer was Engaged Capital, opening a new position worth an estimated $101M. The largest seller was Bellevue Group, cutting an estimated $20.6M.
- 155 institutional investors held Evolent Health (EVH) as of Q3 2020, up from 136 in Q2 2020.
- Funds reported $987M of Evolent Health stock for Q3 2020, up 89% quarter-over-quarter.
- 42 funds opened new Evolent Health positions in Q3 2020 and 23 closed out, a net change of +19 holders.
- The largest Evolent Health buyer in Q3 2020 was Engaged Capital, an estimated $101M added.
- The largest Evolent Health seller in Q3 2020 was Bellevue Group, an estimated $20.6M sold.
Based on aggregated 13F filings for Q3 2020.